MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA that has become a focal point for research into how mitochondria signal their energy status during exercise. This article reviews, for research purposes only, the molecular mechanisms by which experimental models describe MOTS-c influencing lipid β-oxidation under energetic stress.

What MOTS-c is and why exercise matters

Mitochondria are increasingly studied not only as sites of oxidative phosphorylation but as signaling organelles that encode short peptides within their own genome. MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) was identified from a short open reading frame in mitochondrial DNA and characterized as a peptide that influences insulin sensitivity and metabolic homeostasis, with skeletal muscle described as a primary target tissue.¹ Because skeletal muscle is also the tissue that experiences the sharpest swings in energy demand during physical activity, MOTS-c has drawn attention as a candidate node linking mitochondrial status to substrate selection.

Lipid β-oxidation — the stepwise catabolism of fatty acids within the mitochondrial matrix — is a central pathway for sustained energy production when carbohydrate stores are limited. In research models, the question is whether a mitochondrial-encoded peptide can help coordinate the shift toward fatty-acid utilization when cellular energy charge falls. The literature summarized below describes proposed mechanisms; it does not establish clinical outcomes, and human evidence remains limited and largely observational.⁴

The folate–AICAR–AMPK axis

The most frequently cited mechanistic account begins in the folate–methionine one-carbon cycle. In the original characterization, MOTS-c was reported to inhibit the folate cycle and its tethered de novo purine biosynthesis, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMPK activator.¹ Subsequent reviews have organized these observations into an "AICAR–AMPK" framework, in which disruption of the folate–methionine cycle is the upstream event and AMPK activation is the downstream metabolic switch.⁶

AMPK functions as a cellular energy sensor. When the AMP:ATP ratio rises — as it does during intense or prolonged muscular activity — AMPK is activated and reprograms metabolism toward ATP-generating catabolic pathways while restraining ATP-consuming anabolic ones. Within this framework, MOTS-c is positioned as a mitochondrial input that can bias the system toward lipid catabolism. It is important to note that AICAR accumulation and AMPK activation are also driven by exercise itself, so MOTS-c is best understood as one contributor within a redundant network rather than a solitary trigger.⁴

AMPK, ACC and the malonyl-CoA gate

Once AMPK is active, a well-established biochemical consequence in skeletal muscle is phosphorylation and inhibition of acetyl-CoA carboxylase (ACC). ACC produces malonyl-CoA, which is both a substrate for fatty-acid synthesis and an allosteric inhibitor of carnitine palmitoyltransferase 1 (CPT1), the transporter that admits long-chain fatty acids into the mitochondrial matrix. Lowering malonyl-CoA therefore relieves inhibition of CPT1 and permits a higher rate of fatty-acid entry for β-oxidation.¹⁰

This AMPK–ACC–malonyl-CoA–CPT1 relay is not unique to MOTS-c; it is a general control point through which several energy-sensing signals converge on fatty-acid oxidation. The proposed contribution of MOTS-c is to feed into this relay from the mitochondrial side. Studies in adipose and hepatic tissue have reported that MOTS-c treatment is accompanied by AMPK pathway activation and lower circulating and hepatic fatty-acid levels in rodent models, and that pharmacological AMPK blockade attenuates these effects — consistent with an AMPK-dependent mechanism.⁷

De novo lipogenesis and lipid synthesis

The same AMPK-driven inhibition of ACC that opens the CPT1 gate also lowers the malonyl-CoA pool available for de novo lipogenesis. In an in-vitro study of aged human mesenchymal stem cells, MOTS-c exposure was associated with AMPK activation, inhibition of mTORC1, and decreased lipid synthesis, alongside reduced reactive oxygen species production.⁸ Research models thus describe a coordinated shift in which fatty acids are directed toward oxidation rather than storage, though the magnitude and tissue specificity of this shift vary across experimental systems.

Mitochondrial biogenesis and oxidative capacity

Fatty-acid oxidation is constrained by the amount and quality of mitochondrial machinery available. Several reports connect MOTS-c signaling to the AMPK/PGC-1α axis that governs mitochondrial biogenesis. In a study of endurance-trained animals and human runners, endurance training was associated with increased MOTS-c secretion and enhanced skeletal-muscle mitochondrial respiration, with the authors attributing the effect to activation of the AMPK/PGC-1α pathway.⁵ PGC-1α is the principal transcriptional coactivator for genes controlling mitochondrial DNA replication and oxidative metabolism, and it drives expression of downstream factors such as TFAM that support transcription of the mitochondrial genome.

The following table summarizes markers commonly used in this line of research to interpret changes in mitochondrial content and oxidative capacity. These are analytical readouts reported in experimental models, not clinical measures.

Retrograde signaling: MOTS-c in the nucleus

A distinctive feature of MOTS-c is that it appears to act not only in the cytosol but also in the nucleus. Under metabolic stress such as glucose restriction, MOTS-c has been reported to translocate to the nucleus in an AMPK-dependent manner and to regulate a broad set of nuclear genes, including those bearing antioxidant response elements (ARE).² In that work, MOTS-c interacted with stress-responsive transcription factors including NFE2L2/NRF2, positioning the peptide as a participant in mitonuclear communication rather than a purely cytosolic effector.

This dual localization is mechanistically relevant to lipid oxidation for two reasons. First, transcriptional control lets the peptide influence the enzymatic capacity for β-oxidation over a longer time scale than acute allosteric changes at ACC and CPT1. Second, the coupling of oxidative gene programs with antioxidant-response genes is consistent with a model in which increased fatty-acid flux is accompanied by adjustments to redox-buffering capacity. The retrograde signaling concept remains an active research area, and the precise promoter interactions in skeletal muscle during exercise are not fully resolved.²

Exercise as the physiological trigger

The link between MOTS-c and exercise is where the most direct human data exist, though these data are observational. In a study spanning young, middle-aged, and old mice, MOTS-c administration was reported to enhance physical performance and to regulate nuclear genes related to metabolism and proteostasis; in humans, exercise induced endogenous MOTS-c expression in skeletal muscle and in circulation.³ A focused review of mitochondrial-derived peptides and exercise concluded that acute high-intensity exercise can raise humanin and MOTS-c concentrations in skeletal muscle and plasma, while noting that evidence for chronic training-induced changes is conflicting and depends on training mode, intensity, duration, and participant characteristics.⁴

More recent work reported that circulating MOTS-c levels correlate with aerobic exercise capacity in both marathon runners and mice, suggesting the peptide may serve as a candidate biomarker of endurance status.⁵ A recurring theme across this literature is that exercise and MOTS-c share overlapping but not identical pathways: genetic models indicate distinct as well as convergent routes through which physical activity and MOTS-c evoke metabolic changes.⁴ Investigators studying MOTS-c in this context, alongside related mitochondrial modulators such as NAD+, therefore typically design experiments that account for workload, duration, and training history rather than treating the peptide in isolation.

Systemic lipid handling and metabolomic readouts

Beyond intracellular signaling, several reports describe systemic changes in lipid handling in MOTS-c–treated rodent models. In an ovariectomy model of metabolic dysfunction, MOTS-c was associated with increased brown adipose activation, reduced fat accumulation, and lower fatty-acid content in serum and liver, effects that were attenuated by AMPK blockade.⁷ These observations are consistent with redirection of fatty acids toward oxidative pathways, but they are drawn from disease-model rodents and cannot be extrapolated to human physiology.

Metabolomic profiling is the analytical approach most often used to characterize these shifts. The exercise and aging study applied metabolomic analysis to myoblasts and tissue to map MOTS-c–associated changes in metabolic intermediates.³ Targeted metabolomics of acylcarnitines, free fatty acids, and tricarboxylic-acid-cycle intermediates is a natural complement to signaling and transcriptional assays because it can provide pathway-level confirmation of altered mitochondrial lipid flux. Researchers should treat specific lipid-species changes reported in individual models as context-dependent rather than universal, since mitochondrial density and metabolic demand differ markedly between tissues such as skeletal muscle, liver, and adipose.

Analytical detection of the peptide

Quantifying MOTS-c itself is non-trivial. A validated liquid chromatography–mass spectrometry method developed for anti-doping purposes reported a lower limit of detection near 100 pg/mL in plasma and highlighted substantial discrepancies between mass-spectrometry and commercial ELISA measurements of endogenous levels.⁹ This methodological gap matters for research: assay choice can materially affect reported concentrations, and comparisons across studies using different platforms should be interpreted cautiously.

Research considerations and material quality

Investigations into MOTS-c–driven lipid oxidation depend on peptide material with consistent sequence fidelity and documented purity. Variability in synthesis, incomplete purity validation, or missing analytical documentation can obscure pathway-specific effects on AMPK signaling and mitochondrial lipid handling, and can confound comparisons between laboratories. Because much of the mechanism above rests on relatively small differences in phosphorylation state, gene expression, or metabolite abundance, technical reproducibility is central to interpreting results correctly.

Qovigen supplies research-grade MOTS-C characterized under standardized quality controls, with batch traceability and analytical reporting intended to reduce material-driven variability. For reconstitution and handling in experimental work, laboratories commonly pair peptide stock with bacteriostatic water. These materials are provided for controlled laboratory experimentation only.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.